{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:20:05Z","timestamp":1792012805567,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016512","name":"Center for Companion Animal Health University of California Davis","doi-asserted-by":"crossref","award":["2016-15-F"],"award-info":[{"award-number":["2016-15-F"]}],"id":[{"id":"10.13039\/100016512","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Graduate Student Support Program through the Research and Education in Advanced Clinical Health through UC Davis School of Veterinary Medicine","award":["2019-MSO"],"award-info":[{"award-number":["2019-MSO"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prior studies have suggested that pimobendan is associated with several positive effects in cats, including improved survival in cats with congestive heart failure and improved left atrial function in research colony cats with hypertrophic cardiomyopathy (HCM) and normal cats. However, there is still a paucity of pharmacodynamic data refuting or supporting the use of pimobendan in a clinical cat population. This clinical trial aimed to evaluate the pharmacodynamic effects and tolerability of a single dose of pimobendan in cats with HCM. Echocardiograms and Doppler-derived systolic blood pressures were performed in 21 client-owned cats with subclinical HCM at baseline and 90-min after oral administration of 1.25\u2009mg of pimobendan (Vetmedin). Seven additional cats were evaluated post-placebo administration to account for intra-day variability.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Heart rate, systolic blood pressure, and murmur grade were not significantly different between baseline and post-pimobendan evaluations. Left auricular blood flow velocity, left atrial size, and left ventricular fractional shortening were not significantly different between baseline and post-pimobendan evaluations.<\/jats:p>\n                <jats:p>Mean (\u00b1 standard deviation) tissue Doppler peak systolic velocity of the mitral annulus was significantly higher following pimobendan (7.4\u2009cm\/s\u2009\u00b1\u20091.5 vs 8.5\u2009\u00b1\u20091.6; <jats:italic>p<\/jats:italic>\u2009=\u20090.02). Median (min, max) left-ventricular outflow tract maximum velocity was significantly higher following pimobendan [1.9\u2009m\/sec (1.5, 3.4) vs 2.6\u2009m\/sec (2.0, 4.0); <jats:italic>p<\/jats:italic>\u2009=\u20090.01]. Mean right-ventricular outflow tract maximum velocity was also significantly higher following pimobendan (1.5\u2009m\/s\u2009\u00b1\u20090.51 vs 2.0\u2009\u00b1\u20090.53; <jats:italic>p<\/jats:italic>\u2009=\u20090.004). Mean left atrial fractional shortening was significantly higher following pimobendan (28%\u2009\u00b1\u20096 vs 32%\u2009\u00b1\u20097; <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n                <jats:p>No adverse events were observed following pimobendan administration.<\/jats:p>\n                <jats:p>Right ventricular outflow tract velocity was significantly higher following placebo in control cats (1.02\u2009\u00b1\u20090.21 versus 1.31\u2009\u00b1\u20090.31; <jats:italic>p<\/jats:italic>\u2009=\u20090.01). No other significant differences were detected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In client-owned cats with HCM, pimobendan acutely increased left atrial function and mildly increased left ventricular systolic function. Left ventricular outflow tract velocity was increased after pimobendan. Pimobendan was well tolerated in the acute setting in cats with HCM. The findings of this prospective, acute-dosing study confirm previous findings in research animals and retrospective analyses and suggest that chronic dosing studies are safe and warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-02799-9","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T14:43:48Z","timestamp":1614091428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"17","author":[{"given":"Maureen S.","family":"Oldach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Ontiveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Fousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance C.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-5745","authenticated-orcid":false,"given":"Joshua A.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"issue":"1","key":"2799_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jvim.14885","volume":"32","author":"A Boswood","year":"2018","unstructured":"Boswood A, Gordon SG, H\u00e4ggstr\u00f6m J, Wess G, Stepien RL, Oyama MA, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical Myxomatous mitral valve disease receiving Pimobendan or placebo: the EPIC study. J Vet Intern Med. 2018;32(1):72\u201385.","journal-title":"J Vet Intern Med"},{"key":"2799_CR2","unstructured":"Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012\/08\/30. 2012;22(4):398\u2013408."},{"key":"2799_CR3","unstructured":"Summerfield NJ, Boswood A, O\u2019Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med. 2012\/10\/20. 2012;26(6):1337\u201349."},{"key":"2799_CR4","unstructured":"Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med. 2002\/06\/04. 2002;16(3):255\u201361."},{"issue":"6","key":"2799_CR5","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jvim.14586","volume":"30","author":"A Boswood","year":"2016","unstructured":"Boswood A, H\u00e4ggstr\u00f6m J, Gordon SG, Wess G, Stepien RL, Oyama MA, et al. Effect of Pimobendan in dogs with preclinical Myxomatous mitral valve disease and cardiomegaly: the EPIC study\u2014a randomized clinical trial. J Vet Intern Med. 2016;30(6):1765\u201379.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2799_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jvim.13914","volume":"30","author":"AC Vollmar","year":"2016","unstructured":"Vollmar AC, Fox PR. Long-term outcome of Irish wolfhound dogs with preclinical cardiomyopathy, atrial fibrillation, or both treated with Pimobendan, benazepril hydrochloride, or Methyldigoxin Monotherapy. J Vet Intern Med. 2016;30(2):553\u20139.","journal-title":"J Vet Intern Med"},{"key":"2799_CR7","unstructured":"Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. J Vet Cardiol. 2015\/05\/27. 2015;17(2):120\u20138."},{"key":"2799_CR8","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1016\/j.jvc.2015.03.008","volume":"17","author":"JR Payne","year":"2015","unstructured":"Payne JR, Brodbelt DC, Luis FV. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J Vet Cardiol. 2015;17:S244\u201357.","journal-title":"J Vet Cardiol"},{"issue":"11","key":"2799_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2460\/javma.234.11.1398","volume":"234","author":"CE Paige","year":"2009","unstructured":"Paige CE, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc. 2009;234(11):1398\u2013403.","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2799_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from ESC. Eur Heart J. 2008;29(2):270\u20136.","journal-title":"Eur Heart J"},{"issue":"3","key":"2799_CR11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jvim.15745","volume":"34","author":"V Luis Fuentes","year":"2020","unstructured":"Luis Fuentes V, Abbott J, Chetboul V, C\u00f4t\u00e9 E, Fox PR, H\u00e4ggstr\u00f6m J, et al. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J Vet Intern Med. 2020;34(3):1062\u201377.","journal-title":"J Vet Intern Med"},{"key":"2799_CR12","unstructured":"Fox PR, Keene BW, Lamb K, Schober KA, Chetboul V, Luis Fuentes V, et al. International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study. J Vet Intern Med. 2018\/04\/17. 2018;32(3):930\u201343."},{"key":"2799_CR13","doi-asserted-by":"crossref","unstructured":"Reina-Doreste Y, Stern JA, Keene BW, Tou SP, Atkins CE, Defrancesco TC, et al. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure. J Am Vet Med Assoc. 2014;245(5).","DOI":"10.2460\/javma.245.5.534"},{"key":"2799_CR14","doi-asserted-by":"crossref","unstructured":"Oldach MS, Ueda Y, Ontiveros ES, Fousse SL, Harris SP, Stern JA. Cardiac effects of a single dose of Pimobendan in cats with hypertrophic cardiomyopathy; a randomized, placebo-controlled, crossover study. Front Vet Sci. 2019;6.","DOI":"10.3389\/fvets.2019.00015"},{"issue":"March","key":"2799_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jvc.2020.02.002","volume":"28","author":"M Baron Toaldo","year":"2020","unstructured":"Baron Toaldo M, Pollesel M, Diana A. Effect of pimobendan on left atrial function: an echocardiographic pilot study in 11 healthy cats. J Vet Cardiol. 2020;28(March):37\u201347.","journal-title":"J Vet Cardiol"},{"key":"2799_CR16","doi-asserted-by":"crossref","unstructured":"Payne JR, Borgeat K, Brodbelt DC, Connolly DJ, Luis Fuentes V. Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. J Vet Cardiol. 2016\/01\/19. 2015;17 Suppl 1:S318\u201328.","DOI":"10.1016\/j.jvc.2015.09.008"},{"key":"2799_CR17","unstructured":"Johns SM, Nelson OL, Gay JM. Left atrial function in cats with left-sided cardiac disease and pleural effusion or pulmonary edema. J Vet Intern Med. 2012\/07\/19. 2012;26(5):1134\u20139."},{"issue":"6","key":"2799_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/00005344-200006000-00011","volume":"35","author":"R Ishiki","year":"2000","unstructured":"Ishiki R, Ishihara H, Izawa H, Nagata K, Hirai M, Yokota M. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol. 2000;35(6):897\u2013905.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2799_CR19","unstructured":"Asanoi H, Ishizaka S, Kameyama T, Ishise H, Sasayama S. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol. 1994\/02\/01. 1994;23(2):268\u201374."},{"issue":"9","key":"2799_CR20","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1161\/01.CIR.92.9.2645","volume":"92","author":"PR Fox","year":"1995","unstructured":"Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy: an animal model of human disease. Circulation. 1995;92(9):2645\u201351.","journal-title":"Circulation."},{"key":"2799_CR21","unstructured":"Payne J, Luis Fuentes V, Boswood A, Connolly D, Koffas H, Brodbelt D. Population characteristics and survival in 127 referred cats with hypertrophic cardiomyopathy (1997 to 2005). J Small Anim Pr. 2010\/10\/30. 2010;51(10):540\u20137."},{"key":"2799_CR22","unstructured":"Kotkar KD, Said SM, Dearani JA, Schaff H V. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg. 2017\/09\/26. 2017;6(4):329\u201336."},{"key":"2799_CR23","unstructured":"Musat D, Sherrid M V. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu Kardiyol Derg. 2006\/12\/13. 2006;6 Suppl 2:9\u201317."},{"key":"2799_CR24","unstructured":"Vetmedin (pimobendan) [package insert]. Boehringer Ingleheim Vetmedica, Inc., St. Joseph, MO. 2012;"},{"issue":"1","key":"2799_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2460\/javma.241.1.89","volume":"241","author":"SG Gordon","year":"2012","unstructured":"Gordon SG, Saunders AB, Roland RM, Winter RL, Drourr L, Achen SE, et al. Effect of oral administration of pimobendan in cats with heart failure. J Am Vet Med Assoc. 2012 Jul;241(1):89\u201394.","journal-title":"J Am Vet Med Assoc"},{"key":"2799_CR26","doi-asserted-by":"crossref","unstructured":"Gordon SG, C\u00f4t\u00e9 E. Pharmacotherapy of feline cardiomyopathy: Chronic management of heart failure. Vol. 17, Journal of Veterinary Cardiology. Elsevier B.V.; 2015. p. S159\u201372.","DOI":"10.1016\/j.jvc.2015.03.009"},{"key":"2799_CR27","doi-asserted-by":"crossref","unstructured":"Ward JL, Kussin EZ, Tropf MA, Tou SP, DeFrancesco TC, Keene BW. Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy. J Vet Intern Med. 2020;(May):1\u201312.","DOI":"10.1111\/jvim.15920"},{"key":"2799_CR28","doi-asserted-by":"crossref","unstructured":"MacGregor JM, Rush JE, Laste NJ, Malakoff RL, Cunningham SM, Aronow N, et al. Use of pimobendan in 170 cats (2006-2010). J Vet Cardiol. 2011.","DOI":"10.1016\/j.jvc.2011.08.001"},{"key":"2799_CR29","unstructured":"Ueda Y, Stern JA. A one health approach to hypertrophic cardiomyopathy. Yale J Biol Med. 2017;90(3)."},{"issue":"4","key":"2799_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jvc.2016.07.001","volume":"18","author":"M Yata","year":"2016","unstructured":"Yata M, McLachlan AJ, Foster DJR, Hanzlicek AS, Beijerink NJ. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats. J Vet Cardiol. 2016;18(4):310\u201325.","journal-title":"J Vet Cardiol"},{"issue":"1","key":"2799_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stemcr.2018.11.015","volume":"12","author":"R Cohn","year":"2019","unstructured":"Cohn R, Thakar K, Lowe A, Ladha FA, Pettinato AM, Romano R, et al. A contraction stress model of hypertrophic cardiomyopathy due to sarcomere mutations. Stem Cell Reports. 2019;12(1):71\u201383.","journal-title":"Stem Cell Reports"},{"key":"2799_CR32","unstructured":"Payne JR, Borgeat K, Connolly DJ, Boswood A, Dennis S, Wagner T, et al. Prognostic indicators in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2013\/10\/19. 2013;27(6):1427\u201336."},{"issue":"2","key":"2799_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2460\/ajvr.67.2.250","volume":"67","author":"V Chetboul","year":"2006","unstructured":"Chetboul V, Carlos Sampedrano C, Tissier R, Gouni V, Saponaro V, Nicolle AP. Quantitative assessment of velocities of the annulus of the left atrioventricular valve and left ventricular free wall in healthy cats by use of two-dimensional color tissue Doppler imaging. Am J Vet Res. 2006;67(2):250\u20138.","journal-title":"Am J Vet Res"},{"issue":"4","key":"2799_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295\u2013303.","journal-title":"N Engl J Med"},{"issue":"4","key":"2799_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2460\/javma.237.4.402","volume":"237","author":"MJ Acierno","year":"2010","unstructured":"Acierno MJ, Seaton D, Mitchell MA, Da Cunha A. Agreement between directly measured blood pressure and pressures obtained with three veterinary-specific oscillometric units in cats. J Am Vet Med Assoc. 2010;237(4):402\u20136.","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"2799_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/vec.12011","volume":"23","author":"MJ Acierno","year":"2013","unstructured":"Acierno MJ, Fauth E, Mitchell MA, da Cunha A. Measuring the level of agreement between directly measured blood pressure and pressure readings obtained with a veterinary-specific oscillometric unit in anesthetized dogs. J Vet Emerg Crit Care. 2013;23(1):37\u201340.","journal-title":"J Vet Emerg Crit Care"},{"issue":"2","key":"2799_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.vaa.2019.11.001","volume":"47","author":"SA Cerejo","year":"2020","unstructured":"Cerejo SA, Teixeira-Neto FJ, Garofalo NA, Pimenta EL, Zanuzzo FS, Klein AV. Effects of cuff size and position on the agreement between arterial blood pressure measured by Doppler ultrasound and through a dorsal pedal artery catheter in anesthetized cats. Vet Anaesth Analg. 2020;47(2):191\u20139.","journal-title":"Vet Anaesth Analg"},{"key":"2799_CR38","doi-asserted-by":"crossref","unstructured":"Visser LC, Kaplan JL, Nishimura S, Gunther-Harrington CT, B\u00e9langer C, Oldach MS, et al. Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias. J Vet Intern Med. 2018;32(4).","DOI":"10.1111\/jvim.15224"},{"key":"2799_CR39","doi-asserted-by":"crossref","unstructured":"Nishimura S, Visser LC, B\u00e9langer C, Oldach MS, Gunther-Harrington CT, Stern JA. Echocardiographic evaluation of velocity ratio, velocity time integral ratio, and pulmonary valve area in dogs with pulmonary valve stenosis. J Vet Intern Med. 2018;32(5).","DOI":"10.1111\/jvim.15244"},{"key":"2799_CR40","volume-title":"Veterinary echocardiography","author":"JA Boon","year":"2011","unstructured":"Boon JA. Veterinary echocardiography, vol. 1. 2nd ed. West Sussex, UK: Wiley-Blackwell; 2011. 632 p.","edition":"2"},{"key":"2799_CR41","doi-asserted-by":"crossref","unstructured":"2019 ACVIM Forum Research Abstract Program. J Vet Intern Med. 2019;33(5).","DOI":"10.1111\/jvim.15597"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-021-02799-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T14:52:49Z","timestamp":1614091969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-02799-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-02799-9","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted at the University of California Davis School of Veterinary Medicine with IACUC approval of the University of California-Davis. Written informed client consent to participate was obtained for each enrolled patient in this veterinary clinical trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as potential conflict of interest. Joshua A. Stern served as a section editor for BMC at the time of study submission, which did not alter the handling of this manuscript in any way.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}